Stockscreener 앱 받기
1.46
0.00%
0.00
시간 외 거래:
1.48
0.02
+1.37%
NanoViricides Inc 주식(NNVC)의 최신 뉴스
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - citybuzz -
NanoViricdes Surges on Winning ODD Status - Baystreet.ca
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - Lelezard
NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment - Yahoo Finance
FDA orphan tag gives NanoViricides measles drug tax credits, fee waiver - Stock Titan
Is NanoViricides (NNVC) stock forming a clear pattern | Q1 2026: Profit Exceeds ViewsDividend Safety - Newser
NNVC Forecast, Price Target & Analyst Ratings | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC (NanoViricides Inc.) beats Q1 2026 EPS estimates by 23 percent, but posts a slight post-earnings share decline. - Cổng thông tin điện tử tỉnh Tây Ninh
NNVC NanoViricides exceeds Q1 2026 EPS estimates by 23 percent, but shares drop 4.89 percent on zero quarterly revenue.Trading Community - UBND thành phố Hải Phòng
NanoViricides says NV-387 could address measles outbreaks as cases rise globally - Yahoo Finance
Deadly Measles Cases Accentuate the Need for a - One News Page
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow - AOL.com
Profit Recap: Can NanoViricides Inc continue delivering strong returns2026 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387ICYMI - Proactive financial news
Macro Review: Should I hold or sell GMREPRA now2026 Spike Watch & Community Consensus Stock Picks - baoquankhu1.vn
Weekly Earnings: Is NanoViricides Inc subject to activist investor interestTake Profit & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Summary: Is NanoViricides Inc undervalued by DCF analysisWeekly Gains Report & Stock Timing and Entry Methods - baoquankhu1.vn
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug - Proactive financial news
Growth Value: Can NanoViricides Inc stock double in the next year2026 Technical Overview & Short-Term Trading Alerts - baoquankhu1.vn
Can NanoViricides (NNVC) Stock Go Higher | Price at $1.15, Up 6.48%Day Trade - Newser
Activity Recap: Is NanoViricides Inc forming a bullish divergencePortfolio Value Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
NanoViricides Seeks Rare Pediatric Disease Designation for Measles Treatment Candidate - citybuzz -
Measles Rare Pediatric Disease Drug Designation Application File - GuruFocus
NanoViricides seeks rare pediatric disease status for measles drug NV-387 - Yahoo Finance
About Us - FinancialContent
Aug Shorts: Is NanoViricides Inc forming a breakout pattern2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
NNVC Stock Analysis: NanoViricides Inc Biotech Stock Post 2.55% Daily Dip At $0.93 Level - Xã Vĩnh Công
Can NanoViricides (NNVC) Stock Recover Now | Price at $0.93, Down 2.11%Social Investment Platform - Newser
Small caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - proactiveinvestors.co.uk
NanoViricides to Begin Phase II MPox Clinical Trial in Democratic Republic of Congo - citybuzz -
Small cap wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - Proactive financial news
NanoViricides to begin Phase II trial of MPox treatment in Congo - Proactive financial news
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - ACCESS Newswire
Monkeypox drug trial cleared in Congo as NanoViricides readies dosing - Stock Titan
1.77%
0.25%
자본화:
|
볼륨(24시간):